Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Glucagon

Generic name
Glucagon
Brand name
ATC Code
H04AA01

Pharmacokinetics in children

The following pharmakokinetic parameters were observed in subjects with type 1 diabetes mellitus following the subcutaneous injection of glucagon (SmPC Ogluo):

Age 2-<6 years 6-<12 years 12-<18 years
Dosage 0,5 mg 0,5 mg 1 mg
Cmax (mean) 2300 pg/mL  1600 pg/mL  1900 pg/mL
tmax  41 min 34 min (median) 51 min
AUC0-180min 138900 pg/mL*min 104700 pg/mL*min 134300 pg/mL*min

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Diabetes, severe hypoglycaemia
  • Subcutaneous
    • < 25 kg
      [2] [6]
      • 0.5 mg/dose, once only.

      • If the cause is unknown, administering glucose is always preferred

    • ≥ 25 kg
      [2]
      • 1 mg/dose, once only. Repeat after 20 minutes if necessary..

      • If the cause is unknown, administering glucose is always preferred

  • Intramuscular
    • < 25 kg
      [2]
      • 0.5 mg/dose, once only.

      • If the cause is unknown, administering glucose is always preferred

    • ≥ 25 kg
      [2]
      • 1 mg/dose, once only. Repeat after 20 minutes if necessary.  .

      • If the cause is unknown, administering glucose is always preferred

  • Nasal
    • ≥ 4 years
      [5]
      • 3 mg/dose, once only. in one nostril.  .
Diagnostic agent: determination of C-peptide (insulin reserve)
  • Intravenous
    • 1 month up to 18 years
      [1]
      • 15 microg./kg/dose, once only. Max single dose: 1 mg/dose.
Diagnostic agent: determination of hyperinsulinism
  • Intramuscular
    • 1 month up to 18 years
      [1]
      • 0.1 mg/kg/dose, once only. Max single dose: 1 mg/dose.
Diagnostic agent: determination of GH/ACTH reserve
  • Subcutaneous
    • 1 month up to 18 years
      [3]
      • 0.1 mg/kg/dose, once only. Max single dose: 1 mg/dose.

      • Alternative administration: Intramuscular

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Injection for therapeutic use:

Very common: nausea

Common: hyperglycemia, vomiting, headache

[SmPC Ogluo]

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. Novo Nordisk BV, SmPC Glucagen (RVG 02011) 22-12-2022, www.geneesmiddeleninformatiebank.nl
  3. Noordam C et al, Werkboek Kinderendocrinologie, digitale publicatie op www.nvk.nl (alleen leden), 2010
  4. Eli Lilly Nederland B.V, SmPC Baqsimi (EU/1/19/1406/001-2) 06-02-2020, www.geneesmiddeleninformatiebank.nl
  5. Eli Lilly Nederland B.V., SmPC Baqsimi® 3 mg Nasenpulver (EU/1/19/1406/001) Rev 19, 30-09-2024
  6. Tetris Pharma B.V, SmPC Ogluo (EU/1/20/1523/001; EU/1/20/1523/005) , 07-10-2024, Rev 6

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes